EL7.AI
StocksMedium•19 November 2026•
3 min read

Unable to Confirm Evogene’s Third-Quarter Results Ahead of Scheduled Release on November 19

Key Facts

1Evogene was scheduled to release its third-quarter results on November 19, 2026.
2Nasdaq granted the company an additional 180 days to regain compliance, through March 29, 2027.
3Regaining compliance requires the stock to close at a minimum of $1.00 for 10 consecutive business days.
4EVGN shares closed at $0.35 on November 18, 2026.
5First-half 2026 revenue was about $0.7 million, compared with about $2.9 million in the first half of 2025.

Evogene’s third-quarter 2026 earnings and revenue figures could not be verified, as no original results filing was available to confirm them. The company had announced that the quarter’s results would be released on Thursday, November 19, 2026, according to its release-date announcement. There is therefore no documented basis here to establish earnings per share or revenue, or to compare them with analyst estimates. In a separate filing, Nasdaq had granted the company an additional 180 calendar days to regain compliance with the minimum bid price requirement. The deadline is March 29, 2027, placing the compliance issue in the background of the company’s market position.

Evogene scheduled a call to discuss the results on the day of their release, November 19, at 9:00 a.m. Eastern Time, or 4:00 p.m. Israel time. The announced schedule allows the company to present and discuss the quarter’s results on the same day, according to its release schedule announcement. However, the financial figures cannot be presented as confirmed results based on the available information. The call time therefore remains the disclosed detail concerning discussion of the results, without attributing specific figures to the company or market estimates.

To regain compliance with Nasdaq rules, the stock’s closing price must be at least $1.00 for at least 10 consecutive business days within the deadline period. The company said the exchange’s notice does not immediately affect its listing or the trading of its shares, and that the stock continues to trade under the ticker EVGN. According to EL7 data, the stock closed at $0.35 on November 18, 2026, the session before the scheduled results. No reliable verification of the stock’s daily trading range in that session is available. Nasdaq’s filing sets out the price and duration criteria that must be met to regain compliance.

Evogene said it may consider a reverse stock split among the options available to address the compliance shortfall if the issue is not resolved within the deadline. This falls within Nasdaq’s deadline, which expires on March 29, 2027, and spans 180 calendar days. As for the first half of 2026, revenue was about $0.7 million, compared with about $2.9 million in the same period of 2025, according to the company. Evogene attributed a key part of the decline to lower Casterra revenue, noting that the first half of 2025 included about $2.0 million in seed sales. These figures provide historical context for the company’s business, but do not establish the third-quarter result.

In the second quarter of 2026, Evogene revenue was about $0.3 million, compared with about $0.5 million in the second quarter of 2025. The company linked the decline mainly to the expiration of AgPlenus’s agreement with Bayer in May 2026. In its first-half update, Evogene said it had 6 active drug development collaborations with biotechnology companies and academic institutions. It also reported cash and cash equivalents of about $9.3 million as of June 30, 2026, while consolidated cash use was about $2.1 million in the second quarter. The company describes its business as using computational chemistry to design small molecules for drugs and agricultural products.

Open on chart